Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: A clinical-practice-based forecast

Inflammation and Allergy - Drug Targets

Volumn 9, Issue 1, 2010, Pages 6-9

  Actis, Giovanni C ^a   Pellicano, Rinaldo ^b   David, Ezio ^b   Sapino, Anna ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Azathioprine; Chemoprevention; Colorectal cancer; Ulcerative colitis

Indexed keywords

AZATHIOPRINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COLON MUCOSA; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MUCOSA INFLAMMATION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TISSUE REPAIR; ULCERATIVE COLITIS; VALIDATION STUDY;

EID: 77949372602     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152810791292863     Document Type: Article

References (32)

1. Baumgart, D.C.; Sandborn, W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007, 369, 1641-57.
2. Truelove, S.C.; Witts, L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J., 1955, 2(4947), 1041-8.
3. Schwartz, M.; Cohen, R. Optimizing conventional therapy for inflammatory bowel disease. Curr. Gastroenterol, Rep., 2008, 10(6), 585-90.
4. Nakamura, K.; Honda, K.; Mizutani, T.; Akiho, H.; Harada, N. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J. Gastroenterol., 2006, 12(29), 4628-35.
5. Danese, S. Negative regulators of angiogenesis in inflammatory bowel disease: thrombospondin in the spotlight. Pathobiology, 2008, 75(1), 22-4.
6. Liang, H.L.; Ouyang, Q. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J. Gastroenterol., 2008, 14(1), 114-9.
7. Sands, B.E.; Sandborn, W.J.; Feagan, B.; Löfberg, R.; Hibi, T.; Wang, T.; Gustofson, L.M.; Wong, C.J.; Vandervoort, M.K.; Hanauer, S. Adacolumn Study Group. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology, 2008, 135(2), 400-9.
8. Su, C. Outcomes of placebo therapy in inflammatory bowel disease. Inflamm. Bowel Dis., 2006, 12(4), 328-3.
9. Cruickshank, S.M.; McVay, L.D.; Baumgart, D.C.; Felsburg, P.J.; Carding, S.R. Colonic epithelial cell mediated suppression of CD4 T cell activation. Gut, 2004, 53(5), 678-84.
10. Xie, J.; Itzkowitz, S.H. Cancer in inflammatory bowel disease. World J. Gastroenterol., 2008, 14(3), 378-89.
11. Egan, L.J.; Sandborn, W.J. Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology, 1998, 115(5), 1295-6.
12. Dallegri, F.; Ottonello, L.; Ballestrero, A.; Bogliolo, F.; Ferrando, F.; Patrone, F. Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut, 1990, 31(2), 184-6.
13. Dubuquoy, L.; Rousseaux, C.; Thuru, X.; Peyrin-Biroulet, L.; Romano, O.; Chavatte, P.; Chamaillard, M.; Desreumaux, P. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut, 2006, 55(9), 1341-49.
14. Bean, R.H. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med. J. Aust., 1962, 49, 592-3.
15. Tiede, I.; Fritz, G.; Strand, S.; Poppe, D.; Dvorsky, R.; Strand, D.; Lehr, H.A.; Wirtz, S.; Becker, C.; Atreya, R.; Mudter, J.; Hildner, K.; Bartsch, B.; Holtmann, M.; Blumberg, R.; Walczak, H.; Iven, H.; Galle, P.R.; Ahmadian, M.R.; Neurath MF. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin . Invest., 2003, 111(8), 1133-45.
16. Itzkowitz, S.H.; Yio, X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 287(1), G7-17.
17. Rutter, M.; Saunders, B.; Wilkinson, K.; Rumbles, S.; Schofield, G.; Kamm, M.; Williams, C.; Price, A.; Talbot, I.; Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology, 2004, 126(2), 451-9.
18. Fraser, A.G.; Orchard, T.R.; Jewell, D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut, 2002, 50(4), 485-9.
19. Baron, J.H.; Connel, A.M.; Lennard-Jones, J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br. Med. J., 1964, 1(5375), 89-92.
20. Actis, G.C; Fadda, M.; David, E.; Sapino A.Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol., 2007, 27, 7-13.
21. van Staa, T.P.; Card, T.; Logan, R.F.; Leufkens, H.G. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut, 2005, 54(11), 1573-8.
22. Velayos, F.S.; Terdiman, J.P.; Walsh, J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am . J. Gastroenterol., 2005, 100(6), 1345-53.
23. Rubin, D.T.; Lashner, B.A. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am. J. Gastroenterol., 2005, 100(6), 1354-6.
24. D'Haens, G.; Geboes, K.; Ponette, E.; Penninckx, F.; Rutgeerts, P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology, 1997, 112, 1475-81.
25. D'Haens, G.; Geboes, K.; Rutgeerts, P. Endoscopic and histologic healing of Crohn's (ileo) colitis with azathioprine. Gastrointest. Endosc., 1999, 50, 667-71.
26. Blank, M.; Shiloh Y. Programs for cell death: apoptosis is only one way to go. Cell Cycle, 2007, 6(6), 6-95.
27. McIntire, C.R.; Yeretssian, G.; Saleh, M. Inflammasomes in infection and inflammation. Apoptosis, 2009, 14, 522-35.
28. Vogler, M.; Dinsdale D.; Dyer M.J.S.; Cohen G.M. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ., 2009, 16, 360-7.
29. Matula, S.; Croog, V.; Itzkowitz, S.; Harpaz, N.; Bodian, C.; Hossain, S.; Ullman, T. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin. Gastroenterol. Hepatol., 2005, 3(10), 1015-21.
30. Allgayer, H.; Kruis, W. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin. Gastroenterol. Hepatol.. 2006, 4(4), 521; author reply 521.
31. Actis, G.C.; Fadda, M.; Pellicano, R.; David, E.; Rizzetto, M.; Sapino, A. The 17-year single-center experience with the use of azathioprine to maintain remission in ulcerative colitis. Biomed. Pharmacother., 2009, 63, 362-5.
32. Etchevers, M.J.; Aceituno, M.; Sans, M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J. Gastroenterol., 2008, 14(36), 5512-18.